• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016.

作者信息

Raab Marc S, Fink Leah, Schoen Paul, Gonzalez-McQuire Sebastian, Flinois Alain, Cavo Michele, Mateos Maria-Victoria, Yong Kwee

机构信息

Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.

Kantar Health, Montrouge, France.

出版信息

Br J Haematol. 2019 Jun;185(5):981-984. doi: 10.1111/bjh.15680. Epub 2018 Nov 22.

DOI:10.1111/bjh.15680
PMID:30467828
Abstract
摘要

相似文献

1
Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016.2014年至2016年欧洲多发性骨髓瘤治疗实践的演变
Br J Haematol. 2019 Jun;185(5):981-984. doi: 10.1111/bjh.15680. Epub 2018 Nov 22.
2
Multiple myeloma: practice patterns across Europe.多发性骨髓瘤：欧洲各地的诊疗模式
Br J Haematol. 2016 Oct;175(1):66-76. doi: 10.1111/bjh.14193. Epub 2016 Jun 13.
3
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.多发性骨髓瘤治疗领域：欧洲国际指南建议和临床实践。
Expert Rev Hematol. 2018 Mar;11(3):219-237. doi: 10.1080/17474086.2018.1437345. Epub 2018 Feb 16.
4
Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014.多发性骨髓瘤治疗的演变及其对透析独立性的影响：来自法国1999年至2014年队列的数据。
Blood Cancer J. 2016 Mar 25;6(3):e409. doi: 10.1038/bcj.2016.17.
5
Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan.真实世界中大型全国健康计划中多发性骨髓瘤患者的流行病学、治疗模式和生存情况。
Leuk Res. 2019 Oct;85:106219. doi: 10.1016/j.leukres.2019.106219. Epub 2019 Aug 23.
6
The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma.嵌合抗原受体T细胞疗法治疗多发性骨髓瘤的未来
Biol Blood Marrow Transplant. 2019 Mar;25(3):e73-e75. doi: 10.1016/j.bbmt.2018.11.009. Epub 2018 Nov 16.
7
Five decades of therapy for multiple myeloma: a paradigm for therapeutic models.五十年的多发性骨髓瘤治疗：治疗模式的范例
Leukemia. 2005 Jun;19(6):910-2. doi: 10.1038/sj.leu.2403728.
8
Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.美国社区肿瘤实践中复发/难治性多发性骨髓瘤的真实世界治疗模式及相关无进展生存期。
Expert Rev Hematol. 2016 Jul;9(7):707-17. doi: 10.1080/17474086.2016.1195254. Epub 2016 Jun 16.
9
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).Connect MM 登记研究（2010-2016 年）中多发性骨髓瘤二线治疗患者的异质性。
Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):480-485.e3. doi: 10.1016/j.clml.2018.04.007. Epub 2018 May 4.
10
Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014.大剂量美法仑自体干细胞移植预处理后多发性骨髓瘤的早期复发疾病：一项基于2005年至2014年丹麦多发性骨髓瘤登记处的研究
Leukemia. 2018 Sep;32(9):2054-2057. doi: 10.1038/s41375-018-0057-5. Epub 2018 Feb 22.

引用本文的文献

1
Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.NF-ĸB2 和 TRAF3 基因遗传多态性对硼替佐米为基础的治疗多发性骨髓瘤患者反应的影响。
Asian Pac J Cancer Prev. 2024 Mar 1;25(3):829-837. doi: 10.31557/APJCP.2024.25.3.829.
2
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results.复发/难治性多发性骨髓瘤的难治性患者：临床试验结果综述
EJHaem. 2023 Aug 2;4(4):1117-1131. doi: 10.1002/jha2.743. eCollection 2023 Nov.
3
Real-world experience of novel multiple myeloma treatments in a large, single-center cohort in Finland.
芬兰一个大型单中心队列中新型多发性骨髓瘤治疗的真实世界经验。
EJHaem. 2023 Oct 6;4(4):1019-1029. doi: 10.1002/jha2.802. eCollection 2023 Nov.
4
Isatuximab plus carfilzomib and dexamethasone in patients with early late relapsed multiple myeloma: IKEMA subgroup analysis.伊沙佐米联合卡非佐米和地塞米松治疗早期和晚期复发多发性骨髓瘤患者：IKEMA 亚组分析。
Haematologica. 2024 Feb 1;109(2):604-616. doi: 10.3324/haematol.2023.283073.
5
Low-dose decitabine plus bortezomib-dexamethasone therapy is well-tolerated and highly effective on first-relapsed multiple myeloma: a single-center phase 2 trial.低剂量地西他滨联合硼替佐米-地塞米松治疗对首次复发的多发性骨髓瘤耐受性良好且疗效显著：一项单中心2期试验
Am J Cancer Res. 2023 Apr 15;13(4):1611-1616. eCollection 2023.
6
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.基于既往治疗线数和难治状态的复发多发性骨髓瘤患者使用isatuximab联合卡非佐米和地塞米松治疗：IKEMA亚组分析
Am J Hematol. 2023 Jan;98(1):E15-E19. doi: 10.1002/ajh.26602. Epub 2022 Jun 4.
7
Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data.中国新诊断多发性骨髓瘤基于硼替佐米的治疗方案：12年真实世界数据报告
Front Pharmacol. 2020 Dec 11;11:561601. doi: 10.3389/fphar.2020.561601. eCollection 2020.